董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Catherine J. Mackey | 女 | Director | 68 | 22.75万美元 | 未持股 | 2023-08-15 |
| Richard B. Hancock | 男 | Director | 64 | 19.25万美元 | 未持股 | 2023-08-15 |
| Nicholas S. Green | 男 | Director and President and Chief Executive Officer | 59 | 646.18万美元 | 未持股 | 2023-08-15 |
| Esther M. Alegria | 女 | Director | 64 | 22.25万美元 | 未持股 | 2023-08-15 |
| Jeanne A. Thoma | 女 | Director | 63 | 22.75万美元 | 未持股 | 2023-08-15 |
| Joseph Carleone | 男 | non-executive Chairman of the Board and Director | 76 | 25.75万美元 | 未持股 | 2023-08-15 |
| Gregory P. Sargen | 男 | Director | 57 | 22.75万美元 | 未持股 | 2023-08-15 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Daniel R. Hart | 男 | Chief Financial Officer | 49 | 193.69万美元 | 未持股 | 2023-08-15 |
| Nicholas S. Green | 男 | Director and President and Chief Executive Officer | 59 | 646.18万美元 | 未持股 | 2023-08-15 |
| Richard A. Richieri | 男 | Chief Operations Officer | 58 | 110.94万美元 | 未持股 | 2023-08-15 |
| Matthew R. Kwietniak | 男 | Chief Commercial Officer | 54 | 128.39万美元 | 未持股 | 2023-08-15 |
| Mark R. Ziebell | 男 | Vice President, General Counsel and Corporate Secretary | 59 | 137.74万美元 | 未持股 | 2023-08-15 |
董事简历
中英对照 | 中文 | 英文- Catherine J. Mackey
-
Catherine J. Mackey，自2015年2月起担任董事，目前是CYPrus Therapeutics, Inc.（私营小分子制药研发公司）的首席执行官，她于2015年2月加入该公司。她也是MindPiece Partners的顾问（有效），她于2011年成立该公司。她此前于2001年至2010年12月间担任Pfizer的全球研发高级副总裁；此前担任Pfizer康涅狄格州研发总部的战略联盟副总裁；更早领导Pfizer的染色体和蛋白质研究。 在加入Pfizer之前，她在DEKALB Genetics Corporation（被Monsanto Company收购）担任渐升职位，包括企业副总裁与研发主管。她目前是Sequenom, Inc. （NASDAQ： SQNM）（2015.6起）， Cour Pharmaceutical Development Company（2014.3起）和Evolve Biosystems, Inc.（2014.6起）的董事；2011年至2013年2月间担任 YM Biosciences Inc. （被Gilead Sciences Inc.收购）的董事；2010年12月至2013年4月间担任Althea Technologies, Inc. （被Ajinomoto Co., Inc.收购）的董事。她于1977年和1983年分别获得了Cornell University的微生物学学士和博士学位。
Catherine J. Mackey,was appointed to the Board of Directors in July 2019. Dr. Mackey is an experienced leader, director and advisor with more than 30 years of research and development and operations experience in the pharmaceutical, biotechnology and agricultural industries. Currently she serves on the Boards of IDEAYA Biosciences (NASDAQ:IDYA) and Voyager Therapeutics (NASDAQ:VYGR). Previously, she served on the Boards of Directors of COUR, Trillium Therapeutics, Poseida Therapeutics, GW Pharma, Evolve Biosystems, Sequenom, Viventia Bio, YM Biosciences, and Althea Technologies. Dr. Mackey previously served as Senior Vice President of Pfizer Worldwide Research and Development and Director of Pfizer's La Jolla Laboratories, where she built Pfizer La Jolla into one of Pfizer's main pharmaceutical research and development sites with over 1,000 employees and a robust drug pipeline. Prior to that role, she served as head of Strategic Alliances and Genomic and Proteomic Sciences for Pfizer. Dr. Mackey spent the first part of her career in agricultural biotechnology, including as Vice President of DEKALB Genetics, Inc., an international researcher, producer, and marketer of seed. Dr. Mackey received her B.S. and Ph.D. degrees in microbiology from Cornell University. - Catherine J. Mackey，自2015年2月起担任董事，目前是CYPrus Therapeutics, Inc.（私营小分子制药研发公司）的首席执行官，她于2015年2月加入该公司。她也是MindPiece Partners的顾问（有效），她于2011年成立该公司。她此前于2001年至2010年12月间担任Pfizer的全球研发高级副总裁；此前担任Pfizer康涅狄格州研发总部的战略联盟副总裁；更早领导Pfizer的染色体和蛋白质研究。 在加入Pfizer之前，她在DEKALB Genetics Corporation（被Monsanto Company收购）担任渐升职位，包括企业副总裁与研发主管。她目前是Sequenom, Inc. （NASDAQ： SQNM）（2015.6起）， Cour Pharmaceutical Development Company（2014.3起）和Evolve Biosystems, Inc.（2014.6起）的董事；2011年至2013年2月间担任 YM Biosciences Inc. （被Gilead Sciences Inc.收购）的董事；2010年12月至2013年4月间担任Althea Technologies, Inc. （被Ajinomoto Co., Inc.收购）的董事。她于1977年和1983年分别获得了Cornell University的微生物学学士和博士学位。
- Catherine J. Mackey,was appointed to the Board of Directors in July 2019. Dr. Mackey is an experienced leader, director and advisor with more than 30 years of research and development and operations experience in the pharmaceutical, biotechnology and agricultural industries. Currently she serves on the Boards of IDEAYA Biosciences (NASDAQ:IDYA) and Voyager Therapeutics (NASDAQ:VYGR). Previously, she served on the Boards of Directors of COUR, Trillium Therapeutics, Poseida Therapeutics, GW Pharma, Evolve Biosystems, Sequenom, Viventia Bio, YM Biosciences, and Althea Technologies. Dr. Mackey previously served as Senior Vice President of Pfizer Worldwide Research and Development and Director of Pfizer's La Jolla Laboratories, where she built Pfizer La Jolla into one of Pfizer's main pharmaceutical research and development sites with over 1,000 employees and a robust drug pipeline. Prior to that role, she served as head of Strategic Alliances and Genomic and Proteomic Sciences for Pfizer. Dr. Mackey spent the first part of her career in agricultural biotechnology, including as Vice President of DEKALB Genetics, Inc., an international researcher, producer, and marketer of seed. Dr. Mackey received her B.S. and Ph.D. degrees in microbiology from Cornell University.
- Richard B. Hancock
-
Richard B. Hancock，他于2017年11月被任命为董事会成员，并于2019年5月至2020年7月担任Avid Bioservices, Inc.临时总裁兼首席执行官。他曾在生物CDMO行业工作超过30年，担任各种运营和执行职务，最近担任Althea Technologies, Inc.的总裁和首席执行官，这是一个大分子CDMO生产各种生物制品，疫苗和非注射产品。除了Althea，他曾担任The Immune Response Corporation和Hybritech Inc.（现在是Eli Lilly & Company的一部分）的高级管理职务，他目前是Argonaut Manufacturing Services, Inc.的董事会主席和执行董事。一家专注于生物技术和生命科学行业的私营CDMO公司。他获得迈阿密大学微生物学学士学位。
Richard B. Hancock,was appointed to the Board of Directors in November 2017 and served as Avid Bioservices, Inc. interim President and Chief Executive Officer from May 2019 to July 2020. Mr. Hancock has worked in the biologic CDMO industry for over 30 years in various operational and executive roles, serving most recently as President and Chief Executive Officer of Althea Technologies, Inc., a large molecule CDMO producing a wide range of biologics, vaccines and parenteral products. In addition to Althea, Mr. Hancock has held senior management positions at The Immune Response Corporation, and Hybritech Inc. (now part of Eli Lilly & Company), and he is currently the Executive Chairman of Argonaut Manufacturing Services, Inc., a privately-owned CDMO focused on the biotechnology and life sciences industries. Mr. Hancock has served on the Board of Directors of Tempo Therapeutics, a privately-held company focused on cell therapy and vaccine technology, since 2016 and as Executive Chairman of BioCina, a CDMO, focused on the development and cGMP manufacture of microbial-based therapeutics since January 2022. Mr. Hancock received a B.A. in Microbiology from Miami University. - Richard B. Hancock，他于2017年11月被任命为董事会成员，并于2019年5月至2020年7月担任Avid Bioservices, Inc.临时总裁兼首席执行官。他曾在生物CDMO行业工作超过30年，担任各种运营和执行职务，最近担任Althea Technologies, Inc.的总裁和首席执行官，这是一个大分子CDMO生产各种生物制品，疫苗和非注射产品。除了Althea，他曾担任The Immune Response Corporation和Hybritech Inc.（现在是Eli Lilly & Company的一部分）的高级管理职务，他目前是Argonaut Manufacturing Services, Inc.的董事会主席和执行董事。一家专注于生物技术和生命科学行业的私营CDMO公司。他获得迈阿密大学微生物学学士学位。
- Richard B. Hancock,was appointed to the Board of Directors in November 2017 and served as Avid Bioservices, Inc. interim President and Chief Executive Officer from May 2019 to July 2020. Mr. Hancock has worked in the biologic CDMO industry for over 30 years in various operational and executive roles, serving most recently as President and Chief Executive Officer of Althea Technologies, Inc., a large molecule CDMO producing a wide range of biologics, vaccines and parenteral products. In addition to Althea, Mr. Hancock has held senior management positions at The Immune Response Corporation, and Hybritech Inc. (now part of Eli Lilly & Company), and he is currently the Executive Chairman of Argonaut Manufacturing Services, Inc., a privately-owned CDMO focused on the biotechnology and life sciences industries. Mr. Hancock has served on the Board of Directors of Tempo Therapeutics, a privately-held company focused on cell therapy and vaccine technology, since 2016 and as Executive Chairman of BioCina, a CDMO, focused on the development and cGMP manufacture of microbial-based therapeutics since January 2022. Mr. Hancock received a B.A. in Microbiology from Miami University.
- Nicholas S. Green
-
Nicholas S. Green，他于2020年7月被任命为董事会成员，并担任Avid Bioservices, Inc.的总裁兼首席执行官。他在全球制药和医疗保健服务行业拥有超过30年的经验，在新型制药产品的合同制造方面具有重要的专业知识，最近自2011年4月以来担任总裁和therure Biopharma的首席执行官。该公司是一家总部位于加拿大的生物制药公司，旗下包括Therapure Biomanufacturing。在此职位上，他监督了therure的CDMO业务的增长，同时也领导了therure专有血浆蛋白业务的创建，名为Evolve。在Therapure之前，他担任过许多高级管理职务，最著名的是Nipa Laboratories Ltd.的董事总经理，Clariant International Ltd.在美国的生命科学部门的主管，Rhodia Pharma Solutions Ltd.的总裁兼首席执行官，Codexis, Inc.的制药部门的总裁。他持有伦敦玛丽女王学院（Queen Mary College）的化学学士学位和哈德斯菲尔德大学（University of Huddersfield）的工商管理硕士学位。
Nicholas S. Green,was appointed to the Board of Directors and as Avid Bioservices, Inc. President and Chief Executive Officer in July 2020. Mr. Green has more than 30 years of experience in the global pharmaceutical and healthcare services industry with significant expertise in the contract manufacturing of novel pharmaceutical products, having most recently served since April 2011 as the president and chief executive officer of Therapure Biopharma, a Canada-based biopharmaceutical company which includes Therapure Biomanufacturing. In this role, he oversaw the growth of Therapure's CDMO business, while also leading the creation of Therapure's proprietary plasma protein business, named Evolve. Prior to Therapure, Mr. Green held a number of senior management roles, most notably managing director of Nipa Laboratories Ltd., head of the life science division of Clariant International Ltd. in the USA, president and CEO of Rhodia Pharma Solutions Ltd. and president of Codexis, Inc.'s pharma division. Mr. Green holds a bachelor's degree in chemistry from Queen Mary College in London and an MBA from the University of Huddersfield. - Nicholas S. Green，他于2020年7月被任命为董事会成员，并担任Avid Bioservices, Inc.的总裁兼首席执行官。他在全球制药和医疗保健服务行业拥有超过30年的经验，在新型制药产品的合同制造方面具有重要的专业知识，最近自2011年4月以来担任总裁和therure Biopharma的首席执行官。该公司是一家总部位于加拿大的生物制药公司，旗下包括Therapure Biomanufacturing。在此职位上，他监督了therure的CDMO业务的增长，同时也领导了therure专有血浆蛋白业务的创建，名为Evolve。在Therapure之前，他担任过许多高级管理职务，最著名的是Nipa Laboratories Ltd.的董事总经理，Clariant International Ltd.在美国的生命科学部门的主管，Rhodia Pharma Solutions Ltd.的总裁兼首席执行官，Codexis, Inc.的制药部门的总裁。他持有伦敦玛丽女王学院（Queen Mary College）的化学学士学位和哈德斯菲尔德大学（University of Huddersfield）的工商管理硕士学位。
- Nicholas S. Green,was appointed to the Board of Directors and as Avid Bioservices, Inc. President and Chief Executive Officer in July 2020. Mr. Green has more than 30 years of experience in the global pharmaceutical and healthcare services industry with significant expertise in the contract manufacturing of novel pharmaceutical products, having most recently served since April 2011 as the president and chief executive officer of Therapure Biopharma, a Canada-based biopharmaceutical company which includes Therapure Biomanufacturing. In this role, he oversaw the growth of Therapure's CDMO business, while also leading the creation of Therapure's proprietary plasma protein business, named Evolve. Prior to Therapure, Mr. Green held a number of senior management roles, most notably managing director of Nipa Laboratories Ltd., head of the life science division of Clariant International Ltd. in the USA, president and CEO of Rhodia Pharma Solutions Ltd. and president of Codexis, Inc.'s pharma division. Mr. Green holds a bachelor's degree in chemistry from Queen Mary College in London and an MBA from the University of Huddersfield.
- Esther M. Alegria
-
Esther M. Alegria于2021年6月被任命为董事会成员。Alegria博士在生物制药行业拥有超过28年的经验，目前担任APIE Therapeutics的首席执行官，领导一个由经验丰富的行业专家组成的团队，专注于推动特发性肺纤维化和心力衰竭的新疗法的临床开发。在加入APIE之前，Alegria博士是Catalyst Excel & Advance的总裁和高级执行生物制药顾问，这是一家咨询公司，为致力于推出新的制药和生物制药公司的高管提供运营指导。加入Catalyst之前，她曾担任Biogen, Inc.的多个职位，最近担任全球制造高级副总裁，负责公司在丹麦、马萨诸塞州和北卡罗来纳州的成功制造业务。这些设施包括大规模原料药生产、医疗设备组装、制成品和小分子生产业务。Alegria博士还在惠氏（Wyeth）（现为辉瑞（Pfizer））的研发部门担任越来越重要的职位，在那里她获得了Prevnar开发和推出分析技术的公司奖。她持有Hawaii大学的化学博士学位，以及Harvard business School的执行商业管理认证。
Esther M. Alegria,has served as an Executive Consultant and Advisor with The LaSalle Group, an executive consulting firm, since May 2025. Dr. Alegria has over 25 years of experience in successful advancements of vaccines and therapeutic drugs from R&D through commercialization. Previously, she was the Founder of APIE Therapeutics, a preclinical stage pharmaceutical company, where she served as the Chief Executive Officer from 2020 to 2023 and Chief Innovation Officer from 2023 to 2025. Dr. Alegria founded Catalyst Excel & Advance, an advisory firm providing operational guidance to senior executives working to launch new pharmaceutical and biopharmaceutical companies, which she operated from 2016 to 2020. From 2005 to 2015, Dr. Alegria held positions of increasing responsibility at Biogen, Inc., most recently as Senior Vice President, Global Manufacturing, where she was responsible for the company's successful manufacturing operations in Denmark, Massachusetts and North Carolina. Prior to 2005, Dr. Alegria held positions of increasing responsibilities at Banner Pharmacaps, Inc. and Wyeth (R&D Vaccines). Dr. Alegria served as a director of AVID Bioservices, Inc. from 2021 to 2025 (until its sale). She is currently a member of the Board of Trustees for the Puerto Rico Science, Technology and Research Trust, where she focuses on economic and business development in the life science landscape. - Esther M. Alegria于2021年6月被任命为董事会成员。Alegria博士在生物制药行业拥有超过28年的经验，目前担任APIE Therapeutics的首席执行官，领导一个由经验丰富的行业专家组成的团队，专注于推动特发性肺纤维化和心力衰竭的新疗法的临床开发。在加入APIE之前，Alegria博士是Catalyst Excel & Advance的总裁和高级执行生物制药顾问，这是一家咨询公司，为致力于推出新的制药和生物制药公司的高管提供运营指导。加入Catalyst之前，她曾担任Biogen, Inc.的多个职位，最近担任全球制造高级副总裁，负责公司在丹麦、马萨诸塞州和北卡罗来纳州的成功制造业务。这些设施包括大规模原料药生产、医疗设备组装、制成品和小分子生产业务。Alegria博士还在惠氏（Wyeth）（现为辉瑞（Pfizer））的研发部门担任越来越重要的职位，在那里她获得了Prevnar开发和推出分析技术的公司奖。她持有Hawaii大学的化学博士学位，以及Harvard business School的执行商业管理认证。
- Esther M. Alegria,has served as an Executive Consultant and Advisor with The LaSalle Group, an executive consulting firm, since May 2025. Dr. Alegria has over 25 years of experience in successful advancements of vaccines and therapeutic drugs from R&D through commercialization. Previously, she was the Founder of APIE Therapeutics, a preclinical stage pharmaceutical company, where she served as the Chief Executive Officer from 2020 to 2023 and Chief Innovation Officer from 2023 to 2025. Dr. Alegria founded Catalyst Excel & Advance, an advisory firm providing operational guidance to senior executives working to launch new pharmaceutical and biopharmaceutical companies, which she operated from 2016 to 2020. From 2005 to 2015, Dr. Alegria held positions of increasing responsibility at Biogen, Inc., most recently as Senior Vice President, Global Manufacturing, where she was responsible for the company's successful manufacturing operations in Denmark, Massachusetts and North Carolina. Prior to 2005, Dr. Alegria held positions of increasing responsibilities at Banner Pharmacaps, Inc. and Wyeth (R&D Vaccines). Dr. Alegria served as a director of AVID Bioservices, Inc. from 2021 to 2025 (until its sale). She is currently a member of the Board of Trustees for the Puerto Rico Science, Technology and Research Trust, where she focuses on economic and business development in the life science landscape.
- Jeanne A. Thoma
-
Jeanne A. Thoma，她于2020年12月被任命为董事会成员。Thoma女士是一位制药行业高管，拥有超过30年的产品开发和商业化、运营和供应链管理经验。她最近担任SPI Pharma Inc.的总裁兼首席执行官，这是一家全球性的药物成分公司和成分和药物输送系统的创新解决方案提供商。在加入SPI之前，Thoma女士在瑞士生物技术公司Lonza AG担任职务，最近担任微生物控制业务部门的总裁和首席运营官。在加入龙沙之前，她在巴斯夫公司（BASF Corporation）的制药解决方案业务工作了14年，期间她在销售、营销和运营领域担任各种领导职务。Thoma女士目前担任ANI Pharmaceuticals （NASDAQ：ANIP）的董事会成员，是其审计和财务委员会的成员，也是Vectura Group plc的高级独立董事。
Jeanne A. Thoma,was appointed to the Board of Directors in December 2020.She most recently served as president and chief executive officer of SPI Pharma Inc., a global pharmaceuticals ingredients company and an innovative solutions provider of ingredients and drug delivery systems. Prior to SPI, Ms. Thoma held positions of increasing responsibility at Lonza AG, a Switzerland-based CDMO and Life Science company, most recently as president and chief operating officer of the microbial control business sector. Before joining Lonza, she spent 14 years within the pharma solutions business at BASF Corporation, during which she held various leadership positions in the areas of sales, marketing and operations. Ms. Thoma is currently a member of the board of directors of ANI Pharmaceuticals (NASDAQ:ANIP), and is a member of its Audit and Finance Committee and Compensation Committee, Nanoform Finland Plc (HEL:NANOFH) and is a member of its Audit and Compensation Committee and Pharmathen S.A., a private company where she is the chair of the Nomination and Compensation committee. Ms. Thoma was formerly a member of the board of directors of Vectura Group plc. (LSE:VEC). Ms. Thoma holds a B.S. from Montclair State University and an M.B.A. from Fairleigh Dickinson University. - Jeanne A. Thoma，她于2020年12月被任命为董事会成员。Thoma女士是一位制药行业高管，拥有超过30年的产品开发和商业化、运营和供应链管理经验。她最近担任SPI Pharma Inc.的总裁兼首席执行官，这是一家全球性的药物成分公司和成分和药物输送系统的创新解决方案提供商。在加入SPI之前，Thoma女士在瑞士生物技术公司Lonza AG担任职务，最近担任微生物控制业务部门的总裁和首席运营官。在加入龙沙之前，她在巴斯夫公司（BASF Corporation）的制药解决方案业务工作了14年，期间她在销售、营销和运营领域担任各种领导职务。Thoma女士目前担任ANI Pharmaceuticals （NASDAQ：ANIP）的董事会成员，是其审计和财务委员会的成员，也是Vectura Group plc的高级独立董事。
- Jeanne A. Thoma,was appointed to the Board of Directors in December 2020.She most recently served as president and chief executive officer of SPI Pharma Inc., a global pharmaceuticals ingredients company and an innovative solutions provider of ingredients and drug delivery systems. Prior to SPI, Ms. Thoma held positions of increasing responsibility at Lonza AG, a Switzerland-based CDMO and Life Science company, most recently as president and chief operating officer of the microbial control business sector. Before joining Lonza, she spent 14 years within the pharma solutions business at BASF Corporation, during which she held various leadership positions in the areas of sales, marketing and operations. Ms. Thoma is currently a member of the board of directors of ANI Pharmaceuticals (NASDAQ:ANIP), and is a member of its Audit and Finance Committee and Compensation Committee, Nanoform Finland Plc (HEL:NANOFH) and is a member of its Audit and Compensation Committee and Pharmathen S.A., a private company where she is the chair of the Nomination and Compensation committee. Ms. Thoma was formerly a member of the board of directors of Vectura Group plc. (LSE:VEC). Ms. Thoma holds a B.S. from Montclair State University and an M.B.A. from Fairleigh Dickinson University.
- Joseph Carleone
-
Joseph Carleone，他是哲学博士。他于2010年1月1日成为公司的总裁兼首席执行官，此前曾担任公司的总裁兼首席运营官（2006年10月15日以来）。他于2013年3月12日当选为董事会主席。他目前也担任总裁兼董事，任职于American Pacific Corporation（内华达公司）、Ampac-ISP公司、American Azide Corporation、Ampac Farms公司。他也曾担任Ampac Fine Chemicals公司（公司的直接或间接全资子公司）、AMPAC Fine Chemicals Texas公司（公司的直接或间接全资子公司）的董事。他也曾担任Ampac-ISP公司的多个全资子公司的董事（直到2012年7月），包括Ampac Holdings Limited公司（始于2008年）、Ampac ISP Dublin Limited公司、Ampac ISP UK Cheltenham Limited公司（始于2010年）、Ampac ISP UK Westcott Limited公司。从2007年9月到2009年12月，他曾一直担任Reinhold Industries公司（美国和欧洲各种应用程序的高级定制的复合组件和片状成型化合物的多元化制造商）的董事。从2005年11月到2006年9月，他曾担任Irvine Sensors Corporation（一家科技公司从事设计、开发、制造和销售安全产品、软件、视觉系统和小型电子产品，以及更高级别的政府和商业应用防御、信息技术和物理安全系统）的高级副总裁兼首席产品官。从2003年3月到2005年11月，他曾担任Irvine Sensors Corporation的董事会成员。他也曾担任Aerojet Fine Chemicals公司（GenCorp公司的商业单位）的总裁，以及GenCorp公司（航空航天和国防产品和系统制造商，涉及房地产市场）的副总裁（从2000年9月到2005年11月）。从1999年到2000年，他是Aerojet公司的副总裁和总经理，负责遥感系统。此外，他曾担任Aerojet公司的运营副总裁（从1997年到2000年）。
Joseph Carleone,was appointed to the Board of Directors in November 2017, and currently serves as the non-executive Chairman of the Board. Dr. Carleone was Chairman of the Board of AMPAC Fine Chemicals LLC, a leading manufacturer of pharmaceutical active ingredients from 2015 to 2018. Prior to this position, Dr. Carleone was President, Chief Executive Officer and director of American Pacific Corporation, a leading custom manufacturer of fine and specialty chemicals and propulsion products. Dr. Carleone has also served or currently serves as an officer and/or a director of several directly or indirectly wholly-owned subsidiaries of American Pacific Holdings, LLC. Dr. Carleone received his bachelor's degree in mechanical engineering from Drexel University, Philadelphia, Pennsylvania, in 1968; his master's degree in Applied Mechanics from Drexel University in 1970; and his doctorate degree in Applied Mechanics from Drexel University in 1972. Dr. Carleone has served as a director of Sensient Technologies, Inc. (NYSE:SXT) since 2014, and is currently the Lead Director of the Sensient Board and a member of the Audit and Scientific Advisory Committees. - Joseph Carleone，他是哲学博士。他于2010年1月1日成为公司的总裁兼首席执行官，此前曾担任公司的总裁兼首席运营官（2006年10月15日以来）。他于2013年3月12日当选为董事会主席。他目前也担任总裁兼董事，任职于American Pacific Corporation（内华达公司）、Ampac-ISP公司、American Azide Corporation、Ampac Farms公司。他也曾担任Ampac Fine Chemicals公司（公司的直接或间接全资子公司）、AMPAC Fine Chemicals Texas公司（公司的直接或间接全资子公司）的董事。他也曾担任Ampac-ISP公司的多个全资子公司的董事（直到2012年7月），包括Ampac Holdings Limited公司（始于2008年）、Ampac ISP Dublin Limited公司、Ampac ISP UK Cheltenham Limited公司（始于2010年）、Ampac ISP UK Westcott Limited公司。从2007年9月到2009年12月，他曾一直担任Reinhold Industries公司（美国和欧洲各种应用程序的高级定制的复合组件和片状成型化合物的多元化制造商）的董事。从2005年11月到2006年9月，他曾担任Irvine Sensors Corporation（一家科技公司从事设计、开发、制造和销售安全产品、软件、视觉系统和小型电子产品，以及更高级别的政府和商业应用防御、信息技术和物理安全系统）的高级副总裁兼首席产品官。从2003年3月到2005年11月，他曾担任Irvine Sensors Corporation的董事会成员。他也曾担任Aerojet Fine Chemicals公司（GenCorp公司的商业单位）的总裁，以及GenCorp公司（航空航天和国防产品和系统制造商，涉及房地产市场）的副总裁（从2000年9月到2005年11月）。从1999年到2000年，他是Aerojet公司的副总裁和总经理，负责遥感系统。此外，他曾担任Aerojet公司的运营副总裁（从1997年到2000年）。
- Joseph Carleone,was appointed to the Board of Directors in November 2017, and currently serves as the non-executive Chairman of the Board. Dr. Carleone was Chairman of the Board of AMPAC Fine Chemicals LLC, a leading manufacturer of pharmaceutical active ingredients from 2015 to 2018. Prior to this position, Dr. Carleone was President, Chief Executive Officer and director of American Pacific Corporation, a leading custom manufacturer of fine and specialty chemicals and propulsion products. Dr. Carleone has also served or currently serves as an officer and/or a director of several directly or indirectly wholly-owned subsidiaries of American Pacific Holdings, LLC. Dr. Carleone received his bachelor's degree in mechanical engineering from Drexel University, Philadelphia, Pennsylvania, in 1968; his master's degree in Applied Mechanics from Drexel University in 1970; and his doctorate degree in Applied Mechanics from Drexel University in 1972. Dr. Carleone has served as a director of Sensient Technologies, Inc. (NYSE:SXT) since 2014, and is currently the Lead Director of the Sensient Board and a member of the Audit and Scientific Advisory Committees.
- Gregory P. Sargen
-
Gregory P. Sargen于2003年2月加入Cambrex公司。2007年2月，担任副总裁兼财务总监。自2011年1月起担任执行副总裁兼首席财务官。曾担任财务副总裁。此前，从1999年到2002年曾在Exp@nets公司工作，担任各种角色包括执行副总裁，金融/财务总监，副总裁/财务总监。从1996年到1998年，担任飞世尔科技国际化工制造部的财务副总裁和总监。还曾在Merck & Company, Inc., Heat and Control, Inc.，和 Deloitte & Touche。担任财务、会计和审计等职位。
Gregory P. Sargen,was appointed to the Board of Directors in November 2017. Mr. Sargen most recently served as Chief Financial Officer and Executive Vice President, Corporate Development and Strategy of Cambrex Corporation (NYSE:CBM) ("Cambrex"), a global manufacturer and provider of services to life sciences companies, from 2007 until early 2020, when Cambrex was acquired by a private equity company. Mr. Sargen previously served as Executive Vice President, Corporate Development and Strategy, Chief Financial Officer, and Vice President, Finance of Cambrex. Prior to Cambrex, Mr. Sargen served as Executive Vice President, Chief Financial Officer of Expanets, Inc., Vice President of Finance – Chemicals Manufacturing Division of Fisher Scientific International Inc. (n/k/a Thermo Fisher Scientific Inc.) (NYSE:TMO), and held positions with Merck & Co., Inc. (NYSE:MRK), Heat and Control, Inc. and Deloitte & Touche LLP. Mr. Sargen also serves on the board of Protara Therapeutics (NASDAQ:TARA), a drug development company, Kindeva Drug Delivery LLC, a privately held company focused on complex drug delivery solutions, Veranova, a privately held contract development and manufacturer of small molecule active pharmaceutical ingredients, and Umoja Biopharma, a privately held biotechnology company. Mr. Sargen serves as chairman of the Audit Committee for each of the foregoing companies. Mr. Sargen is a Certified Public Accountant (non-practicing) and holds an MBA in Finance from The Wharton School of the University of Pennsylvania and a B.S. in Accounting from Pennsylvania State University. - Gregory P. Sargen于2003年2月加入Cambrex公司。2007年2月，担任副总裁兼财务总监。自2011年1月起担任执行副总裁兼首席财务官。曾担任财务副总裁。此前，从1999年到2002年曾在Exp@nets公司工作，担任各种角色包括执行副总裁，金融/财务总监，副总裁/财务总监。从1996年到1998年，担任飞世尔科技国际化工制造部的财务副总裁和总监。还曾在Merck & Company, Inc., Heat and Control, Inc.，和 Deloitte & Touche。担任财务、会计和审计等职位。
- Gregory P. Sargen,was appointed to the Board of Directors in November 2017. Mr. Sargen most recently served as Chief Financial Officer and Executive Vice President, Corporate Development and Strategy of Cambrex Corporation (NYSE:CBM) ("Cambrex"), a global manufacturer and provider of services to life sciences companies, from 2007 until early 2020, when Cambrex was acquired by a private equity company. Mr. Sargen previously served as Executive Vice President, Corporate Development and Strategy, Chief Financial Officer, and Vice President, Finance of Cambrex. Prior to Cambrex, Mr. Sargen served as Executive Vice President, Chief Financial Officer of Expanets, Inc., Vice President of Finance – Chemicals Manufacturing Division of Fisher Scientific International Inc. (n/k/a Thermo Fisher Scientific Inc.) (NYSE:TMO), and held positions with Merck & Co., Inc. (NYSE:MRK), Heat and Control, Inc. and Deloitte & Touche LLP. Mr. Sargen also serves on the board of Protara Therapeutics (NASDAQ:TARA), a drug development company, Kindeva Drug Delivery LLC, a privately held company focused on complex drug delivery solutions, Veranova, a privately held contract development and manufacturer of small molecule active pharmaceutical ingredients, and Umoja Biopharma, a privately held biotechnology company. Mr. Sargen serves as chairman of the Audit Committee for each of the foregoing companies. Mr. Sargen is a Certified Public Accountant (non-practicing) and holds an MBA in Finance from The Wharton School of the University of Pennsylvania and a B.S. in Accounting from Pennsylvania State University.
高管简历
中英对照 | 中文 | 英文- Daniel R. Hart
Daniel R. Hart自2018年8月起担任首席财务官，拥有超过20年的财务会计和运营经验。Hart先生负责Avid Bioservices, Inc.的会计和财务、信息技术和验证以及项目工程功能。在加入Avid Bioservices, Inc.之前，他曾担任ENO Holdings, Inc.（一家房地产公司）的首席财务官，SM&A（一家航空航天和国防管理咨询公司，此前是纳斯达克上市的公司）的首席财务官，以及各种其他公司，包括Biolase Technology, Inc.（纳斯达克上市的医疗设备制造商）的首席财务官。以及加州科斯塔梅萨的德勤会计师事务所（Deloitte & Touche LLP）。他获得了California Polytechnic State University, San Luis Obispo的会计学士学位，是加利福尼亚州的注册会计师。
Daniel R. Hart,has served as Chief Financial Officer since August 2018 and has over 25 years of financial accounting and operational experience. Prior to joining Avid, Mr. Hart served as Chief Financial Officer of ENO Holdings, Inc. Prior to that, Mr. Hart served SM&A, Inc. for almost a decade in several roles, including most recently as Senior Vice President, Chief Financial Officer. Earlier in his career, Mr. Hart worked in the audit practice of Deloitte & Touche LLP. Mr. Hart holds a Bachelor of Science in business administration with an emphasis in accounting from California Polytechnic State University, San Luis Obispo and is a certified public accountant (inactive).- Daniel R. Hart自2018年8月起担任首席财务官，拥有超过20年的财务会计和运营经验。Hart先生负责Avid Bioservices, Inc.的会计和财务、信息技术和验证以及项目工程功能。在加入Avid Bioservices, Inc.之前，他曾担任ENO Holdings, Inc.（一家房地产公司）的首席财务官，SM&A（一家航空航天和国防管理咨询公司，此前是纳斯达克上市的公司）的首席财务官，以及各种其他公司，包括Biolase Technology, Inc.（纳斯达克上市的医疗设备制造商）的首席财务官。以及加州科斯塔梅萨的德勤会计师事务所（Deloitte & Touche LLP）。他获得了California Polytechnic State University, San Luis Obispo的会计学士学位，是加利福尼亚州的注册会计师。
- Daniel R. Hart,has served as Chief Financial Officer since August 2018 and has over 25 years of financial accounting and operational experience. Prior to joining Avid, Mr. Hart served as Chief Financial Officer of ENO Holdings, Inc. Prior to that, Mr. Hart served SM&A, Inc. for almost a decade in several roles, including most recently as Senior Vice President, Chief Financial Officer. Earlier in his career, Mr. Hart worked in the audit practice of Deloitte & Touche LLP. Mr. Hart holds a Bachelor of Science in business administration with an emphasis in accounting from California Polytechnic State University, San Luis Obispo and is a certified public accountant (inactive).
- Nicholas S. Green
Nicholas S. Green，他于2020年7月被任命为董事会成员，并担任Avid Bioservices, Inc.的总裁兼首席执行官。他在全球制药和医疗保健服务行业拥有超过30年的经验，在新型制药产品的合同制造方面具有重要的专业知识，最近自2011年4月以来担任总裁和therure Biopharma的首席执行官。该公司是一家总部位于加拿大的生物制药公司，旗下包括Therapure Biomanufacturing。在此职位上，他监督了therure的CDMO业务的增长，同时也领导了therure专有血浆蛋白业务的创建，名为Evolve。在Therapure之前，他担任过许多高级管理职务，最著名的是Nipa Laboratories Ltd.的董事总经理，Clariant International Ltd.在美国的生命科学部门的主管，Rhodia Pharma Solutions Ltd.的总裁兼首席执行官，Codexis, Inc.的制药部门的总裁。他持有伦敦玛丽女王学院（Queen Mary College）的化学学士学位和哈德斯菲尔德大学（University of Huddersfield）的工商管理硕士学位。
Nicholas S. Green,was appointed to the Board of Directors and as Avid Bioservices, Inc. President and Chief Executive Officer in July 2020. Mr. Green has more than 30 years of experience in the global pharmaceutical and healthcare services industry with significant expertise in the contract manufacturing of novel pharmaceutical products, having most recently served since April 2011 as the president and chief executive officer of Therapure Biopharma, a Canada-based biopharmaceutical company which includes Therapure Biomanufacturing. In this role, he oversaw the growth of Therapure's CDMO business, while also leading the creation of Therapure's proprietary plasma protein business, named Evolve. Prior to Therapure, Mr. Green held a number of senior management roles, most notably managing director of Nipa Laboratories Ltd., head of the life science division of Clariant International Ltd. in the USA, president and CEO of Rhodia Pharma Solutions Ltd. and president of Codexis, Inc.'s pharma division. Mr. Green holds a bachelor's degree in chemistry from Queen Mary College in London and an MBA from the University of Huddersfield.- Nicholas S. Green，他于2020年7月被任命为董事会成员，并担任Avid Bioservices, Inc.的总裁兼首席执行官。他在全球制药和医疗保健服务行业拥有超过30年的经验，在新型制药产品的合同制造方面具有重要的专业知识，最近自2011年4月以来担任总裁和therure Biopharma的首席执行官。该公司是一家总部位于加拿大的生物制药公司，旗下包括Therapure Biomanufacturing。在此职位上，他监督了therure的CDMO业务的增长，同时也领导了therure专有血浆蛋白业务的创建，名为Evolve。在Therapure之前，他担任过许多高级管理职务，最著名的是Nipa Laboratories Ltd.的董事总经理，Clariant International Ltd.在美国的生命科学部门的主管，Rhodia Pharma Solutions Ltd.的总裁兼首席执行官，Codexis, Inc.的制药部门的总裁。他持有伦敦玛丽女王学院（Queen Mary College）的化学学士学位和哈德斯菲尔德大学（University of Huddersfield）的工商管理硕士学位。
- Nicholas S. Green,was appointed to the Board of Directors and as Avid Bioservices, Inc. President and Chief Executive Officer in July 2020. Mr. Green has more than 30 years of experience in the global pharmaceutical and healthcare services industry with significant expertise in the contract manufacturing of novel pharmaceutical products, having most recently served since April 2011 as the president and chief executive officer of Therapure Biopharma, a Canada-based biopharmaceutical company which includes Therapure Biomanufacturing. In this role, he oversaw the growth of Therapure's CDMO business, while also leading the creation of Therapure's proprietary plasma protein business, named Evolve. Prior to Therapure, Mr. Green held a number of senior management roles, most notably managing director of Nipa Laboratories Ltd., head of the life science division of Clariant International Ltd. in the USA, president and CEO of Rhodia Pharma Solutions Ltd. and president of Codexis, Inc.'s pharma division. Mr. Green holds a bachelor's degree in chemistry from Queen Mary College in London and an MBA from the University of Huddersfield.
- Richard A. Richieri
Richard A. Richieri自2019年10月起担任首席运营官，拥有超过29年的生物制药行业经验，涉及药物发现、CGMP运营、合同制造和工艺开发等领域。Richieri先生曾在Avid Bioservices（当时名为Peregrine Pharmaceuticals）工作了15年，包括担任制造高级副总裁。在此期间，他在启动、建立和发展Avid的CDMO业务以及帮助公司实现生产能力多样化方面发挥了重要作用。在加入公司之前的五年里，他曾担任Syngene International的顾问和生物制剂生产代理主管，Syngene International是一家服务于制药行业的全球性发现、开发和制造组织。Richieri先生拥有加州大学洛杉矶分校化学工程学士学位和加州大学圣迭戈分校化学工程硕士学位。
Richard A. Richieri,has served as Chief Operations Officer since October 2019 and has over 29 years of biopharmaceutical industry experience spanning the areas of drug discovery, CGMP operations, contract manufacturing and process development. Mr. Richieri previously spent 15 years with Avid Bioservices (when it was known as Peregrine Pharmaceuticals), including serving in the role of senior vice president of manufacturing. During that time, he was instrumental in launching, building and growing Avid's CDMO business and helping the company diversify its production capabilities. Prior to joining the Company he spent the previous five years serving as an advisor and acting head of biologics production for Syngene International, a global discovery, development and manufacturing organization serving the pharmaceutical industry. Mr. Richieri holds a Bachelor of Science in chemical engineering from the University of California, Los Angeles and a Masters Degree in chemical engineering from the University of California, San Diego.- Richard A. Richieri自2019年10月起担任首席运营官，拥有超过29年的生物制药行业经验，涉及药物发现、CGMP运营、合同制造和工艺开发等领域。Richieri先生曾在Avid Bioservices（当时名为Peregrine Pharmaceuticals）工作了15年，包括担任制造高级副总裁。在此期间，他在启动、建立和发展Avid的CDMO业务以及帮助公司实现生产能力多样化方面发挥了重要作用。在加入公司之前的五年里，他曾担任Syngene International的顾问和生物制剂生产代理主管，Syngene International是一家服务于制药行业的全球性发现、开发和制造组织。Richieri先生拥有加州大学洛杉矶分校化学工程学士学位和加州大学圣迭戈分校化学工程硕士学位。
- Richard A. Richieri,has served as Chief Operations Officer since October 2019 and has over 29 years of biopharmaceutical industry experience spanning the areas of drug discovery, CGMP operations, contract manufacturing and process development. Mr. Richieri previously spent 15 years with Avid Bioservices (when it was known as Peregrine Pharmaceuticals), including serving in the role of senior vice president of manufacturing. During that time, he was instrumental in launching, building and growing Avid's CDMO business and helping the company diversify its production capabilities. Prior to joining the Company he spent the previous five years serving as an advisor and acting head of biologics production for Syngene International, a global discovery, development and manufacturing organization serving the pharmaceutical industry. Mr. Richieri holds a Bachelor of Science in chemical engineering from the University of California, Los Angeles and a Masters Degree in chemical engineering from the University of California, San Diego.
- Matthew R. Kwietniak
Matthew R. Kwietniak自2021年10月起担任首席商务官，在CDMO产品、临床开发服务和科学产品领域拥有超过30年的销售经验。最近，他在赛默飞世尔制药服务集团担任美洲药品销售主管。在担任这一职务期间，Kwietniak先生因其创纪录的销售增长以及在其任期和领导期间持续超额完成季度和年度目标而受到赞誉。他还曾在LabCorp的子公司Covance，Inc.担任临床开发服务业务的高级销售主管十多年。在科文斯工作期间，Kwietniak先生担任过多个不断升级的销售领导职务，并在临床开发服务部门担任了三年的销售执行总监。在此期间，他扩大并管理了一个由业务开发总监组成的美国商业团队，包括签署了几份大型的III期合同。在他的领导生涯中，他负责发展和支持销售团队，每年创造超过10亿美元的收入。Kwietniak先生拥有新泽西学院工商管理/管理学学士学位。
Matthew R. Kwietniak,has served as Chief Commercial Officer since October 2021 and has over 30 years of sales experience spanning CDMO offerings, clinical development services and scientific products. Most recently he served as head of drug product sales for the Americas within the Pharma Services Group at Thermo Fisher Scientific. In this role, Mr. Kwietniak is credited with record sales growth and consistent overachievement of quarterly and annual goals during his tenure and leadership. He also spent over a decade as a senior sales executive in the Clinical Development Services business at Covance, Inc., a division of LabCorp. Throughout his time with Covance, Mr. Kwietniak held multiple escalating sales leadership roles, culminating in a three-year tenure as Executive Director of sales in the Clinical Development Services division during which time he expanded and managed a U.S. commercial team of Business Development Directors that included the signing of several large Phase III contracts. In his leadership career, he has been responsible for growing and supporting sales teams generating in excess of $1 billion annually. Mr. Kwietniak holds a Bachelor of Science in business administration/management from The College of New Jersey.- Matthew R. Kwietniak自2021年10月起担任首席商务官，在CDMO产品、临床开发服务和科学产品领域拥有超过30年的销售经验。最近，他在赛默飞世尔制药服务集团担任美洲药品销售主管。在担任这一职务期间，Kwietniak先生因其创纪录的销售增长以及在其任期和领导期间持续超额完成季度和年度目标而受到赞誉。他还曾在LabCorp的子公司Covance，Inc.担任临床开发服务业务的高级销售主管十多年。在科文斯工作期间，Kwietniak先生担任过多个不断升级的销售领导职务，并在临床开发服务部门担任了三年的销售执行总监。在此期间，他扩大并管理了一个由业务开发总监组成的美国商业团队，包括签署了几份大型的III期合同。在他的领导生涯中，他负责发展和支持销售团队，每年创造超过10亿美元的收入。Kwietniak先生拥有新泽西学院工商管理/管理学学士学位。
- Matthew R. Kwietniak,has served as Chief Commercial Officer since October 2021 and has over 30 years of sales experience spanning CDMO offerings, clinical development services and scientific products. Most recently he served as head of drug product sales for the Americas within the Pharma Services Group at Thermo Fisher Scientific. In this role, Mr. Kwietniak is credited with record sales growth and consistent overachievement of quarterly and annual goals during his tenure and leadership. He also spent over a decade as a senior sales executive in the Clinical Development Services business at Covance, Inc., a division of LabCorp. Throughout his time with Covance, Mr. Kwietniak held multiple escalating sales leadership roles, culminating in a three-year tenure as Executive Director of sales in the Clinical Development Services division during which time he expanded and managed a U.S. commercial team of Business Development Directors that included the signing of several large Phase III contracts. In his leadership career, he has been responsible for growing and supporting sales teams generating in excess of $1 billion annually. Mr. Kwietniak holds a Bachelor of Science in business administration/management from The College of New Jersey.
- Mark R. Ziebell
Mark R. Ziebell从2012年6月开始担任副总裁、首席法律顾问，从2012年7月开始担任公司秘书，并开展公司与证券法律执业超过19年的时间。加入Peregrine前，从2004年3月到2012年6月，Ziebell先生担任Snell & Wilmer LLP的加利福尼亚州科斯塔梅萨市办事处的合伙人。Ziebell先生代理公众与私人公司范围广泛的公司与证券事务、并购、战略联盟事务和公司治理。他的工作经验涉及多个行业，包括生物制药与生命科学。从1999年到2012年6月，Ziebell先生担任Avid Bioservices, Inc.外部公司法律顾问。Ziebell先生于1986年在美国旧金山大学（University of San Francisco）获得会计学理学士学位，并于1994年在美国旧金山大学（University of San Francisco）法学院获得法学博士学位。获得法学学位前，Ziebell先生担任加利福尼亚州旧金山的德豪会计师事务所（BDO Seidman）的注册会计师。
Mark R. Ziebell,has served as Vice President, General Counsel since June 2012 and Corporate Secretary since July 2012, and has been practicing corporate and securities law for over 25 years. Prior to joining Avid Bioservices, Inc. , Mr. Ziebell was a partner with the Costa Mesa, California office of Snell & Wilmer LLP. Mr. Ziebell has represented public and private companies in a wide range of corporate and securities matters, mergers and acquisitions, strategic alliance matters and corporate governance. He earned his B.S. in accounting in 1986 from the University of San Francisco and his Juris Doctorate in 1994 from the University of San Francisco School of Law. Prior to earning his law degree, Mr. Ziebell was a certified public accountant with BDO Seidman in San Francisco, California.- Mark R. Ziebell从2012年6月开始担任副总裁、首席法律顾问，从2012年7月开始担任公司秘书，并开展公司与证券法律执业超过19年的时间。加入Peregrine前，从2004年3月到2012年6月，Ziebell先生担任Snell & Wilmer LLP的加利福尼亚州科斯塔梅萨市办事处的合伙人。Ziebell先生代理公众与私人公司范围广泛的公司与证券事务、并购、战略联盟事务和公司治理。他的工作经验涉及多个行业，包括生物制药与生命科学。从1999年到2012年6月，Ziebell先生担任Avid Bioservices, Inc.外部公司法律顾问。Ziebell先生于1986年在美国旧金山大学（University of San Francisco）获得会计学理学士学位，并于1994年在美国旧金山大学（University of San Francisco）法学院获得法学博士学位。获得法学学位前，Ziebell先生担任加利福尼亚州旧金山的德豪会计师事务所（BDO Seidman）的注册会计师。
- Mark R. Ziebell,has served as Vice President, General Counsel since June 2012 and Corporate Secretary since July 2012, and has been practicing corporate and securities law for over 25 years. Prior to joining Avid Bioservices, Inc. , Mr. Ziebell was a partner with the Costa Mesa, California office of Snell & Wilmer LLP. Mr. Ziebell has represented public and private companies in a wide range of corporate and securities matters, mergers and acquisitions, strategic alliance matters and corporate governance. He earned his B.S. in accounting in 1986 from the University of San Francisco and his Juris Doctorate in 1994 from the University of San Francisco School of Law. Prior to earning his law degree, Mr. Ziebell was a certified public accountant with BDO Seidman in San Francisco, California.